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http://dx.doi.org/10.1016/j.jacl.2016.0BACKGROUND: Ezetimibe added to statin therapy further reduces LDL-C and clinical atheroscle-
rotic cardiovascular disease compared to statin alone. However, the number of effective and safe
oral agents for patients not at LDL-C goal is limited. In prior clinical trials, gemcabene reduced
LDL-C and was generally well-tolerated in nearly 900 patients treated for up to 12 weeks.
OBJECTIVE: To evaluate the LDL-C lowering and safety of gemcabene as add-on to stable statin
therapy in hypercholesterolemic patients.
METHODS: This was an 8-week, double-blind, placebo-controlled, randomized, phase 2 study in
men and postmenopausal women $18 and #65 years of age with LDL-C $130 mg/dL (3.4 mmol/
L) while on low-intensity to high-intensity stable statin (the majority on moderate intensity) therapy.
Sixty-six patients were randomized 1:1:1 to gemcabene 300 mg, 900 mg, or placebo QD.
RESULTS: Gemcabene 300 mg and 900 mg produced a mean percent change in LDL-C of
223.4 6 4.7% (P 5 .005) and 227.7 6 4.3% (P , .001), respectively, vs 26.2 6 4.3% for placebo.
The median percent change in CRP was 226.1% (P 5 .196) and 253.9% (P , .001) for gemcabene
300 mg and 900 mg, respectively, vs 211.1% for placebo. Gemcabene 300 mg and 900 mg were well-
tolerated with no significant difference in AEs compared to placebo.
CONCLUSIONS: Gemcabene as add-on to stable statin therapy demonstrated additional dose-
dependent and statistically significant reductions in LDL-C of.20% and CRP.40% compared to pla-
cebo. The results support gemcabene-continued development for patients requiring LDL-C lowering
beyond that provided by background statin therapy.
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8.002Introduction
Low-density lipoprotein cholesterol (LDL-C) lowering
is one of the most validated and modifiable of known risk
factors for reducing cardiovascular events. It is also the
basis of virtually all national and international guidelines
for reducing the burden of clinical atherosclerotichis is an open access article under the CC BY-NC-ND license (http://
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cardiovascular outcome trials over the last 25 years, a
robust relationship between absolute lowering in LDL-C
and cardiovascular disease (CVD) has been established
whereby each 1.0 mmol/L (38.7 mg/dL) lowering in
LDL-C reduces the incidence of major coronary events,
coronary revascularizations, and ischemic stroke by
approximately 20%.3 Although the majority of the data
were derived from statin trials, the recent IMPROVE-IT
trial confirmed the LDL-C/ASCVD relationship when a
non-statin, ezetimibe was added to high-dose simvastatin
and compared to simvastatin alone to achieve further
LDL-C lowering.6
Most guidelines for the prevention of CVD recommend
lowering of LDL-C to ,100 mg/dL (,2.59 mmol/L) for
patients considered at high coronary heart disease risk and
,70 mg/dL (,1.81 mmol/L) in patients with established
CVD.7,8 The only major departure from these treatment-
targeted guidelines is the 2013 American College of Cardi-
ology/American Heart Association (ACC/AHA) guidelines,
which focus on individual patient risk and maximizing
statin therapy while de-emphasizing LDL-C goals.8 Guide-
lines from other organizations in the United States such as
the National Lipid Association and the American Associa-
tion of Clinical Endocrinologists continue to emphasize the
NCEP-ATP III treatment goals for LDL-C levels.9,10
Statins, as the first line therapy, are very effective at
lowering LDL-C; however, many patients do not achieve
LDL-C targets with statins alone.11,12 In addition, a small
but significant percentage of patients are unable or unwill-
ing to tolerate effective doses of statins.13 Secondary oral
agents used to achieve additional LDL-C reduction are
often limited by tolerability, side effects, or efficacy; these
include bile acid sequestrants, fibrates, nicotinic acid, and
ezetimibe.14–17 Other agents such as lomitapide, an oral
microsomal triglyceride transfer protein inhibitor,18 and mi-
pomersen, an anti-sense apolipoprotein B synthesis inhibi-
tor administered by subcutaneous injection,19,20 are
approved only for the rare patient population with homozy-
gous familial hypercholesterolemia (HoFH). Both these
lipid-altering agents carry a ‘‘boxed’’ warning for risk of
hepatotoxicity and are administered under a risk evaluation
and mitigation strategy program. The recently approved
proprotein convertase subtilisin/kexin type 9 monoclonal
antibody inhibitors, while being the most effective LDL-
C lowering class to enter routine practice, are very expen-
sive for broad market use and require parenteral administra-
tion every 2 or 4 weeks.21–23 Therefore, there remains a
need for more effective, well-tolerated and safe oral agents
to lower LDL-C levels.
Gemcabene (administered as 6, 6’-oxybis [2, 2-
dimethyl-4-hexanoic acid] monocalcium salt) is a lipid-
regulating compound with a novel mechanism of action
that enhances the clearance of very low density lipoprotein
(VLDL) via the reduction of hepatic apolipoprotein C-III
(apoC-III) messenger RNA (mRNA).24–26 In the early
2000s, seven phase 2 studies were conducted, with theresults from six of these studies never being published.
Integration of the data supports gemcabene as being gener-
ally well tolerated across various patient populations with
significant lowering of LDL-C, apolipoprotein B (apoB),
and C-reactive protein (CRP) in hypercholesterolemia pa-
tients, and significant lowering of triglycerides (TG) and in-
creases in high-density lipoprotein cholesterol (HDL-C) in
hypertriglyceridemic patients. To date, gemcabene has been
administered to 895 healthy subjects and patients and has
been observed to be well tolerated in doses up to 900 mg
once daily (QD) for up to 12 weeks.27,28
In 2011 gemcabene was in-licensed by Gemphire
Therapeutics Inc. for continued development. Herein, we
report data from the first study assessing gemcabene when
added to previously prescribed background statins; an 8-
week, double-blind, placebo-controlled study evaluating
the efficacy and safety of gemcabene in patients whose
LDL-C remained $ 130 mg/dL (3.4 mmol/L) while on
stable statin therapy.Methods
The study was conducted in compliance with good
clinical practices. The study protocol, amendments, and
subject-informed consent documents were approved by
site-specific Institutional Review Boards, and the informed
consent was signed by all participants before performance
of any study-related activity.
Study subjects
From August 2000 to April 2002, patients entered into a
run-in phase of up to 12 weeks whereby other lipid-
lowering agents (fibrates, niacin, and fish oils) were
discontinued and statin doses were stabilized. Patients on
stable statin monotherapy (.3 months) and who met the
eligibility criteria were randomized to an 8-week treatment
phase (NCT02571257). Major inclusion criteria included
men and postmenopausal women 18 to 65 years old and
LDL-C $ 130 mg/dL (3.4 mmol/L). Patients were
excluded if they had TGs . 400 mg/dL, creatine kinase
[CK] . 3 ! the upper limit of normal (ULN); body
mass index . 35 kg/m2; uncontrolled diabetes mellitus
(HbA1C . 10%); renal dysfunction (blood urea nitrogen
[BUN] or creatinine . 2 ! ULN); or hepatic dysfunction
(aspartate aminotransferase [AST] or alanine aminotrans-
ferase [ALT] . 2 ! ULN); myocardial infarction, severe
or unstable angina pectoris, coronary angioplasty, coronary
bypass graft, or any other major cardiovascular event result-
ing in hospitalization in the previous month; or a history of
gall stones or gall bladder disease.
Study design
This was an 8-week, double-blind, placebo-controlled,
randomized, multicenter, phase 2 study in
1214 Journal of Clinical Lipidology, Vol 10, No 5, October 2016hypercholesterolemic patients on stable statin therapy.
Before the screening visit, patient’s statin therapy was
stabilized, and all other lipid-altering medications were
discontinued for at least 12 weeks. Patients with LDL-C $
130 mg/dL at the screening visit (and who continued to
meet entry criteria) remained on their current background
statin therapy and were randomized within 6 weeks 1:1:1 to
either gemcabene 300 mg QD, gemcabene 900 mg QD or
matching placebo for 8 weeks (Fig. 1).
Study procedures
Fasting serum samples for lipid efficacy and key
chemistry assessments (AST, ALT, and CK) were collected
at screening and weeks 0, 2, 4, and 8. More complete
laboratory (hematology and chemistry) analysis was per-
formed at screening and week 8. Elevations of ALT or AST
. 3 ! ULN at 2 consecutive measurements 1 week apart
(63 days) or CK . 10 ! ULN at 2 consecutive
measurements 1 week apart (63 days) were reported as
adverse events and required active management by in-
vestigators. A physical examination was performed at
weeks 0 and 8. At each visit, vital signs were performed
and patients were queried about adverse experiences,
including specific inquiring for signs/symptoms of myalgia,
muscle weakness, or production of brown urine.
Study endpoints
The primary endpoint was the mean percent change
from baseline in LDL-C at week 8. Secondary and
exploratory endpoints included the percent change from
baseline in total cholesterol (TC), TGs, VLDL-C, HDL-C,
apoB, and CRP at week 8. The calculated change from
baseline in non-HDL-C (TC minus HDL-C) is also
reported, as is the Framingham Risk Score. Safety and
tolerability were determined by treatment emergent adverse
event (AE) reporting, clinical laboratory assessments, vital
signs, and physical examination. Clinically significant
abnormal laboratory values or clinically significant changes
in vital signs or physical examinations were recorded as
adverse events.Figure 1 Study design. After patient consent, statin therapy was
stabilized and all other lipid-modifying medications were discon-
tinued during a run-in phase of up to 12 weeks. Patients were
screened (over 6 weeks) and then randomized 1:1:1 to either gem-
cabene 300 mg QD, 900 mg QD, or matching placebo for 8 weeks.
Low-density lipoprotein cholesterol (LDL-C); once daily (QD).Randomization and blinding
Patients were randomized within each site to one of the
three treatment groups. Study medication was shipped to
the sites in fixed block sizes of six. Each patient qualifying
for a treatment assignment was given the next consecutive
number within a site and was dispensed the corresponding
study medication. Gemcabene 300 mg tablets and matching
placebo tablets were supplied by Pfizer Inc. Patients
randomized to the 300-mg dose group were administered
1 ! 300 mg gemcabene and 2 placebo tablets/dose QD;
those randomized to the 900-mg dose group were admin-
istered 3! 300 mg gemcabene tablets/dose QD, and those
randomized to the placebo group were administered 3
placebo tablets/dose QD.
Analytical methods
Medical Research Laboratories (currently PPD Global
Central Laboratories, Highland Heights, Kentucky) was the
central laboratory for measurement of all laboratory
procedures including lipid profile, clinical chemistries,
hematology, and urinalysis. The laboratory was accredited
by the College of American Pathologists and standardized
by the Centers for Disease Control part III Lipid Standard-
ization Program. LDL-C was calculated by the Friedewald
equation.29 VLDL-C was estimated from TG by using the
formula TG/5. HDL-C was measured after precipitation
of apoB containing lipoproteins with dextran sulfate.30
Statistical methods
The efficacy analyses included all patients with at least 1
baseline lipid value and at least 1 postrandomization
measurement. The baseline value was calculated as the
mean of the screening and week 0 measures. If one of the
two baseline measurements was missing, the single avail-
able measurement was used alone. The last double-blind
measurement was carried forward for patients who did not
have a measurement at week 8. All tests were 2-sided and
conducted at the 5% level of significance. A sample size of
69 patients (23 patients per treatment group) was expected
to provide 90% power to detect an absolute difference of
20% between the placebo and gemcabene 900 mg groups in
the mean percent change from baseline in LDL-C. This was
based on the use of a 2-sided t test with a 5% level of sig-
nificance and a standard deviation of 20%.
The mean percent change from baseline in LDL-C at
week 8 was analyzed using an analysis of covariance
(ANCOVA) model with the effects due to treatment,
combined center, and baseline LDL-C value as a covariate.
Adjusted means from the ANCOVA are presented. To
adjust for multiple comparisons, a step-down approach to
testing was used. Treatment-by-center and treatment-by-
baseline interactions were investigated separately. The
Shapiro–Wilk test determined if the residuals from the
ANCOVA analysis were normally distributed. In cases
Stein et al Gemcabene in patients on stable statin therapy 1215where non-normality was indicated, the parameter and its
baseline value were ranked and also analyzed by Conover’s
nonparametric ANCOVA technique, and thus, median
changes were also reported.31
The analysis described for LDL-C was also conducted
for change from baseline in TC, TGs, non-HDL-C, HDL-C,
VLDL-C, apo B, and CRP at week 8. Owing to small
patient numbers, only descriptive statistics by statin-
intensity subgroups was provided for changes in LDL-C.
All patients who received at least 1 dose of study
medication were included in the safety analyses. Descrip-
tive statistics by treatment group were provided for adverse
event data and clinical laboratory data. The incidence of
adverse events was compared by visual inspection between
treatment groups. Descriptive summaries were provided for
changes in vital signs.Results
Subject disposition and baseline characteristics
Of the 211 patients screened, a total of 66 patients were
randomized as follows: 24 to placebo, 20 to gemcabene
300 mg, and 22 to gemcabene 900 mg. A majority of the
screen failures did not meet the inclusion criterion of LDL-
C $ 130 mg/dL. Sixty-one patients completed the study: 3
patients (2 placebo and 1 gemcabene discontinued due to
adverse events and 2 patients withdrew consent; Fig. 2). Pa-
tient demographic and other baseline characteristics are
summarized in Table 1 and were generally similar across
treatment groups, other than LDL-C values, which were
slightly higher in the placebo group and TGs, which were
higher in the 900-mg gemcabene group. The number of pa-
tients with diabetes mellitus was low with 1 (4.2%) patientFigure 2 Patient disposition. A total of 211 patients were
screened, 66 patients were randomized, and 61 patients completed
the study. Withdrew (W/D); adverse event (AE).in the placebo group and 4 (9.5%) patients in the gemca-
bene treatment groups. Approximately 10% of patients
were current smokers, with most patients (approximately
50%) having never smoked. Patients entered the study on
previously established stable low-intensity (n 5 15,
22.7%), moderate-intensity (n 5 39, 59.1%), and high-
intensity (n 5 12, 18.2%) statins.32 Most patients across
treatment groups were receiving moderate-intensity simva-
statin and atorvastatin. Most of the patients entered in the
study had low-to-moderate CVD risk.
Effect on LDL-C and other key parameters
The mean (6SE) percent change in LDL-C from
baseline at week 8 was 223.4 6 4.7% (P 5 .009) for gem-
cabene 300 mg, 227.7 6 4.37% (P , .001) for gemcabene
900 mg and 26.2 6 4.3% for placebo (Fig. 3). LDL-C ef-
fects across statin intensities were highly variable at the
gemcabene 300 mg dose. At the most efficacious gemca-
bene dose (900 mg), LDL-C changes were (n 5 5,
240.6%), (n 5 12, 223.8%), and (n 5 4, 223.8%) on
background low, moderate, and high-intensity statins,
respectively (Table 2).
Parallel reductions were seen in non-HDL-C and apoB
(Fig. 3), with mean (6SE) percent change in non-HDL-C of
219.8 6 4.3% (P 5 .032) and 223.9 6 4.0% (P 5 .004) in
the 300 mg and 900 mg treatment groups, respectively, vs
26.9 6 3.9% with placebo. Mean (6SE) percent change
in apoB was 211.9 6 6.6% (P 5 .301) and 217.2
6 6.0% (P 5 .086) in the 300 mg and 900 mg treatment
groups, respectively, vs 22.80 6 5.7% with placebo.
Median percent change in CRP was 226.1% (P 5 .196)
and 253.9% (P , .001) in the 300 mg and 900 mg treat-
ment groups, respectively, vs 211.1% with placebo
(Fig. 3). In the 900-mg gemcabene treatment group, 75%
(15 of 20) of patients had a CRP lowering of $ 50%, vs
14% (3 of 21) in the placebo group.
Mean (6SE) percent change in TC was 215.6
6 3.5% (P 5 .026) and 219.9 6 3.1% (P 5 .001) in
the 300 mg and 900-mg treatment groups, respectively,
vs 24.8 6 3.1% with placebo. Mean changes in TG
and VLDL-C trended lower in the gemcabene treatment
groups but were not statistically different from placebo.
There was no change in HDL-C vs placebo in this study
(Table 3).
Safety
Treatment-emergent adverse events (Table 4) were expe-
rienced by 45% (9 patients) receiving gemcabene 300 mg
and 72.7% (16 patients) receiving gemcabene 900 mg
compared to 50% (12 patients) receiving placebo. The
most frequently occurring adverse events in the
gemcabene-treatment group were headache (4 patients;
9.5%) and infection (4 patients; 9.5%). The most frequently
occurring adverse event in the placebo group was infection
(3 patients; 12.5%).
Table 1 Baseline characteristics for all randomized patients
Characteristic
Number of patients (%)
Gemcabene 1 Statin
Placebo 1 Statin 300-mg QD 900-mg QD All doses
N 5 24 N 5 20 N 5 22 N 5 42
Sex, N (%)
Men 11 (45.8) 12 (60) 7 (31.8) 19 (45.2)
Women 13 (54.2) 8 (40) 15 (68.2) 23 (54.8)
Race, N (%)
White 20 (83.8) 15 (75) 18 (81.8) 33 (78.6)
Nonwhite 4 (16.7) 5 (25) 3 (13.5) 5 (21.4)
Age (y)
Mean (SE) 57.5 (1.2) 51.2 (1.7) 57.3 (1.5) 54.3 (1.2)
Body mass index (kg/m2)
Mean (SE) 28.5 (0.9) 28.0 (0.9) 27.6 (0.7) 27.8 (0.6)
Smoking, N (%)
Current smoker 2 (9.1) 1 (5.6) 4 (19.0) 5 (12.8)
Never smoked 11 (50.0) 10 (55.6) 9 (42.9) 19 (48.7)
Past smoker 9 (40.9) 7 (38.9) 8 (38.1) 15 (38.5)
Diabetic, N (%)
Yes 1 (4.5) 1 (5.6) 2 (9.5) 3 (7.7)
No 21 (95.5) 17 (94.4) 19 (90.5) 36 (92.3)
Laboratory parameters (mg/dL)
Mean (SE)
LDL-C*,† 157.4 (5.7) 149.6 (6.8) 149.0 (6.1) 149.3 (4.5)
HDL-C* 53.2 (2.5) 51.7 (3.1) 54.5 (2.9) 53.2 (2.1)
Non-HDL-C* 190.6 (6.3) 185.2 (6.8) 185.6 (6.6) 185.4 (4.7)
TG* 168.5 (18.4) 159.5 (17.2) 189.4 (17.9) 175.2 (12.5)
TC* 244.5 (6.4) 234.5 (6.5) 241.1 (6.6) 238.0 (4.6)
Apolipoprotein B* 147 (4.2) 144.6 (4.7) 151.7 (5.5) 148.3 (3.7)
C-reactive protein (mg/L) 4.2 (1.2) 0.7 (0.07) 4.2 (1.1) 3.5 (0.7)
Systolic blood pressure (mm Hg)
Mean (SE) 128.4 (2.4) 123.3 (2.3) 135.8 (2.7) 129.8 (2.0)
Diastolic blood pressure (mm Hg)
Mean (SE) 80.4 (1.5) 77.6 (1.7) 81.5 (1.5) 79.6 (1.1)
Statin therapy, N(%)‡
Low intensity 4 (17) 6 (30) 5 (23) 11 (26)
Moderate intensity 15 (62) 11 (55) 13 (59) 24 (57)
High intensity 5 (21) 3 (15) 4 (18) 7 (17)
SE, Standard error; TG, Triglyceride; TC, total cholesterol.
*Baseline was the mean of screening and week 0.
†Friedewald method unless TG . 400 mg/dL, in which case ultracentrifugation was used.
‡Low-intensity statin therapy included, fluvastatin 40 mg/day, cerivastatin 0.4 mg/day, lovastatin 10-20 mg/day, pravastatin 10-20 mg/day, or sim-
vastatin 10 mg/day. Moderate intensity statin therapy included, atorvastatin , 40 mg/day, pravastatin 40 mg/day, or simvastatin 20-40 mg/day. High
intensity statin therapy included, atorvastatin $ 40 mg/day, simvastatin 80 mg/day. QD, once daily.
1216 Journal of Clinical Lipidology, Vol 10, No 5, October 2016Associated treatment-emergent adverse events (Table 5)
were experienced by 21.4% (300 mg: 4 patients; 900 mg: 5
patients) receiving gemcabene and by 29.2% (7 patients)
receiving placebo. The most common treatment-
associated adverse events in the gemcabene-treatment
group were asthenia, headache, and dizziness (2 patients
each; 4.8%). For the placebo group, the most common
adverse event was vasodilatation (2 patients; 8.3%).
One patient receiving gemcabene 900 mg had a serious
adverse event of iliac occlusive disease requiringhospitalization that was considered unrelated to treatment.
Three patients (2 placebo and 1 gemcabene 300 mg)
withdrew due to adverse events, all of which were
considered possibly related to treatment. There were no
deaths in this study.
Laboratory adverse events
Changes in clinical laboratory assessments (Table 4)
were small, nonsignificant, and generally similar across
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Figure 3 Gemcabene effects on mean percent change in LDL-C, non-HDL-C, ApoB, and median percent change in CRP. LDL-C, low-
density lipoprotein cholesterol; CRP, C-reactive protein; apoB, apolipoprotein B; non-HDL-C, non-high-density lipoprotein cholesterol.
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tions in mean fasting glucose of 29.8 and 23.0 mg/dL
were seen for gemcabene 300 mg and 900 mg,Table 2 Mean change in LDL-C by statin intensity*
Treatment/statin intensity (32) N
Mean baseline
LDL
Placebo 22 158.6
Low-intensity statin 4 150.4
Moderate-intensity statin 14 156.1
High-intensity statin 4 175.8
Gemcabene 300 mg 18 149.1
Low-intensity statin 5 157.4
Moderate-intensity statin 10 144.5
High-intensity statin 3 150.5
Gemcabene 900 mg 21 149.0
Low-intensity statin 5 145.1
Moderate-intensity statin 12 141.0
High-intensity statin 4 178.0
*Low-intensity statin therapy included, fluvastatin 40 mg/day, cerivastatin
vastatin 10 mg/day. Moderate intensity statin therapy included, atorvastatin ,
intensity statin therapy included, atorvastatin $ 40 mg/day, simvastatin 80 mrespectively, vs 20.7 mg/dL for placebo. No meaningful
changes were observed in liver transaminases (ALT and
AST) in patients administered gemcabene as comparedMean final
LDL
Mean % change
baseline LDL
Mean absolute change
baseline LDL
147.1 26.7 211.5
162.0 4.4 11.6
142.0 28.2 214.1
150.0 212.3 225.8
112.7 224.3 236.4
124.8 219.9 232.6
92.8 235.0 251.7
158.7 4.3 8.2
108.0 227.7 241.0
85.4 240.6 259.7
107.3 223.6 233.8
138.5 223.8 239.5
0.4 mg/day, lovastatin 10-20 mg/day, pravastatin 10-20 mg/day, or sim-
40 mg/day, pravastatin 40 mg/day, or simvastatin 20-40 mg/day. High
g/day.
Table 3 Mean percent change in lipids from baseline to last assessment (week 8)*
Lipid parameter
Placebo 1 Statin Gemcabene 1 Statin
N 5 22
300-mg QD 900-mg QD
N 5 18 N 5 21
TC
N 22 18 21
Mean baseline (SE) 243.3 (6.2) 234.5 (6.5) 241.1 (6.6)
Mean week 8 (SE) 231.5 (8.5) 201.4 (11.4) 195.1 (7.2)
Adj. mean % change
(SE)
24.8 (3.1) 215.6 (3.5) 219.9 (3.1)
P value 0.026 0.001
HDL-C
N 22 18 21
Mean baseline (SE) 53.6 (2.6) 52.1 (3.3) 54.6 (3.0)
Mean week 8 (SE) 53.7 (2.8) 52.2 (2.9) 52.9 (3.5)
Adj. mean change
(SE)
0.1 (1.7) 0.2 (1.9) 24.2 (2.9)
P value N/A 0.656 0.265
VLDL-C
N 22 18 21
Mean, baseline (SE) 34.5 (3.8) 32.1 (3.6) 37.9 (3.6)
Mean week 8 (SE) 33.0 (3.6) 29.1 (4.0) 31.9 (3.6)
Adj. mean % change
(SE)
22.0 (5.2) 210.1 (5.9) 214.6 (5.3)
P value N/A 0.3 0.093
TG
N 22 18 21
Mean baseline (SE) 172.4 (18.8) 160.7 (18.1) 189.4 (17.9)
Mean week 8 (SE) 165.0 (18.1) 145.3 (20.2) 159.5 (17.8)
Adj. mean % change
(SE)
22.0 (5.2) 210.1 (5.9) 214.6 (5.3)
P value N/A 0.3 0.093
SE, standard error; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; VLDL-C, very low-density lipoprotein-cholesterol; TG,
triglyceride.
*Week 8 of double-blind treatment or last observation carried forward (LOCF) if Week 8 is missing.
1218 Journal of Clinical Lipidology, Vol 10, No 5, October 2016to placebo. One patient receiving 300-mg gemcabene had
a single transient elevation of CK 5 ! ULN (661 U/L
[ULN 5 120 U/L]), which was not present on repeat
testing. No clinically meaningful changes in physical ex-
aminations or vital signs from baseline to the end of the
study were observed.Discussion
Gemcabene is a lipid-lowering therapy with a novel
mechanism of action. Chow-fed Sprague–Dawley rats
orally administered gemcabene showed a dose-dependent
reduction in hepatic apoC-III mRNA levels, which corre-
lated with the reduction in plasma TG.26 In the same study,
gemcabene also showed a markedly enhanced clearance in
125I-labeled VLDL.26 This is consistent with known effects
of lowering apoCIII including the enhanced clearance of
VLDL remnants, the reduced formation of LDL, andenhanced TG lipolysis by lipoprotein lipase.33,34 In mice
devoid of LDL receptors treatment with gemcabene
60 mg/kg/day for 14 days lowered LDL-C 55%, supporting
a mechanism independent of the hepatic LDL receptor to
reduce plasma LDL levels.25,35 A study assessing the ef-
fects of gemcebene in HoFH patients is currently underway.
Finally, gemcabene showed cytokine-induced inhibition of
CRP promoter activity in PLC/PR5/human hepatocytes.
Site-directed mutagenesis of the C/EBP, Nf-kB, and
STAT sites of human CRP promoter together with gel-
shift assay suggested C/EBP-d as a major player and C/
EBP-b and Nf-kB binding protein as minor players in
gemcabene-mediated down-regulation of CRP transcrip-
tion.36 Taken together, gemcabene’s mechanism of action
should lower the full range of atherogenic particles
(VLDL, IDL, and LDL) resulting in decreases in athero-
genic particle number (apoB), particle cholesterol (non-
HDL-C), and TGs (when elevated); with concomitant
lowering of hsCRP.
Table 4 Overview of adverse events and clinical laboratory changes
Adverse events Placebo 1 Statin
Gemcabene + Statin
300-mg QD 900-mg QD All doses
N (% of patients) N 5 24 N 5 20 N 5 22 N 5 42
All AEs
Mild 6 (25.0) 6 (30.0) 9 (40.9) 15 (35.7)
Moderate 6 (25.0) 3 (15.0) 6 (27.3) 9 (21.4)
Severe 0 (0.0) 0 (0.0) 1 (4.5) 1 (2.4)
Associated AEs by max intensity
Mild 2 (8.3) 2 (10.0) 5 (22.7) 7 (16.7)
Moderate 5 (20.8) 2 (10.0) 0 (0.0) 2 (4.8)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Withdrawals due to AEs
All AEs 2 (8.3) 1 (5.0) 0 (0.0) 1 (2.4)
Associated AEs 2 (8.3) 1 (5.0) 0 (0.0) 1 (2.4)
Serious AEs (not associated) 0 (0.0) 0 (0.0) 1 (4.5) 1 (2.4)
Number of patients who died 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Clinical laboratory changes for all
randomized patients Placebo 1 Stain
Gemcabene + Statin
300-mg QD 900-mg QD All doses
Mean 6 (SE) or frequency (n) N 5 24 N 5 19 N 5 21 N 5 40
Laboratory parameter (units)
ALT (U/L) 20.6 (0.8) 0.8 (2.7) 21.4 (1.8) 20.4 (1.6)
AST (U/L) 20.2 (0.6) 1.3 (1.3) 0.5 (1.3) 0.9 (0.9)
CK (mg/dL) 11.3 (8.5) 20.3 (5.5) 22.0 (4.8) 21.2 (3.6)
Creatinine (mg/dL) 0.0 (0.0) 0 (0.0) 0.1 (0.0) 0.1 (0.0)
BUN total (mg/dL) 0.5 (0.5) 1.6 (0.7) 2.9 (0.7) 2.3 (0.5)
Glucose—fasting (mg/dL) 20.7 (1.5) 29.8 (11.2) 23.0 (4.2) 26.3 (5.7)
ALT (.3 ! ULN) (n) 0 0 0 0
AST (.3 ! ULN) (n) 0 0 0 0
CK (.5 ! ULN) (n) 0 1 0 1
ALT, alanine aminotransferease; AST, aspartate aminotransferase; CK, creatine kinase; BUN, blood urea nitrogen; ULN, upper limit of normal.
Stein et al Gemcabene in patients on stable statin therapy 1219The above effects were observed in this phase 2 study in
patients on background statin therapy and with an average
baseline LDL-C of approximately 150 mg/dL. Gemcabene
300 mg and 900 mg significantly lowered LDL-C 23.4%
and 27.7%, respectively, vs a lowering of 6.2% for placebo.
This resulted in nearly 48% of patients achieving an LDL-C
of , 100 mg/dL. At the most efficacious gemcabene dose
(900 mg), LDL-C reductions were (n5 5, 40.6%), (n5 12,
23.6%), and (n 5 4, 23.8%) on background low, moderate,
and high-intensity statins, respectively. Consistent with the
LDL-C lowering, gemcabene showed reductions in non-
HDL-C and TC and a significant lowering of CRP at
gemcabene 900 mg. As the majority of patients presented
with mild to moderate hypertriglyceridemia, only moderate
and nonstatistically significant lowering of TGs was
observed. However, in a study in hypertriglyceridemic
patients (mean baseline TGs $ 200 mg/dL), gemcabene
produced a correlative and significant decrease in apoCIII
and triglycerides, consistent with gemcabene’s
mechanism.27
Although statins are the most widely used efficacious
oral LDL-C lowering agents, they reduce LDL-C by onlyanother 6% to 7% when the dose is doubled and are
ultimately limited by toxicity.37–39 Additional LDL-C
lowering via a mechanism complementary to that of statins
thus provides greater LDL-C reducing potential and has
recently shown ASCVD beneficial effects. The reduction
in LDL-C with ezetimibe added to simvastatin vs simva-
statin alone in the IMPROVE-IT trial resulted in a signifi-
cant decrease in cardiovascular events.6 In an analysis of
subgroups from IMPROVE-IT, it was noted that patients
with on-treatment LDL-C and hs-CRP below selected
cut-points had fewer ASCVD events compared to patients
with both LDL-C and hs-CRP above these cut-points.40
The LDL-C reductions seen with gemcabene are similar
to those reported for ezetimibe,41 as well as bempedoic
acid (ETC-1002) at doses of 120 mg and 180 mg,42 added
to similar stable statin background therapy. Importantly,
gemcabene has also shown a significant lowering of CRP
of up to 53.9%.
The LDL-C results in this add-on to statin study differ
substantially from those seen in another study where
gemcabene and atorvastatin therapy was administered
concurrently.28 Differences in LDL-C lowering results
Table 5 Summary of all associated treatment emergent adverse events, N (% of patients)
Preferred term
Placebo1 Statin
Gemcabene 1 Statin
300-mg QD 900-mg QD All doses
N 5 24 N 5 20 N 5 22 N 5 42
Abdominal pain 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Asthenia 0 (0.0) 1 (5.0) 1 (4.5) 2 (4.8)
Chest pain 0 (0.0) 0 (0.0) 1 (4.5) 1 (2.4)
Face edema 0 (0.0) 1 (5.0) 0 (0.0) 1 (2.4)
Headache 1 (4.2) 2 (10.0) 0 (0.0) 2 (4.8)
Infection 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Hypertension 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Vasodilatation 2 (8.3) 0 (0.0) 1 (4.5) 1 (2.4)
Constipation 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Dyspepsia 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Nausea 1 (4.2) 1 (5.0) 0 (0.0) 1 (2.4)
Thirst 0 (0.0) 0 (0.0) 1 (4.5) 1 (2.4)
Leukopenia 0 (0.0) 0 (0.0) 1 (4.5) 1 (2.4)
Myalgia 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Myasthenia 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Dizziness 1 (4.2) 1 (5.0) 1 (4.5) 2 (4.8)
Hypesthesia 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Insomnia 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Polyuria 0 (0.0) 0 (0.0) 1 (4.5) 1 (2.4)
Prostatic Disorder 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Number of patients with AEs 7 (29.2) 4 (20) 5 (22.7) 9 (21.4)
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design and patient populations, which underestimates
the LDL-C lowering potential as add-on therapy. This
has been observed with ezetimibe, whereby ezetimibe
administered concurrently with atorvastatin 80 mg re-
sulted in a 6% additional lowering of LDL-C, whereas
ezetimibe administered on background atorvastatin
80 mg resulted in an additional 17%–21% lowering in
LDL-C.41,43
Limitations to the present study are as follows: (1) low
patient numbers limit the ability to make certain conclu-
sions, including the ability to summarize data by entry TG
levels; (2) patients were not on the highest doses of what
today are considered the most efficacious statins, atorvas-
tatin 80 mg, or rosuvastatin 40 mg, which may affect both
the efficacy and safety of gemcabene; (3) we only tested
gemcabene in patients with LDL-C $130 mg/dL, and it is
unknown if the efficacy is the same at lower LDL-C levels
(and levels still not at goal) on stable statin therapy; and (4)
whereas it is highly probably that many of the patients had
heterozygous familial hypercholesterolemia given their
LDL-C $130 mg/dL on moderate dose statin, it is
important to conduct similar studies specifically in such
subjects. Based on the results of IMPROVE-IT and the
likelihood that ezetimibe added to statin will become the
standard of care, it is also important to evaluate the LDL-C
efficacy of gemcabene when added to not only moderate
statin (as in this trial) but also high-dose statin alone and/or
statin/ezetimibe-treated patients who fail to achieve optimalLDL-C. A study is planned in patients needing further
LDL-C lowering on stable high-intensity statin therapy,
which will address the utility of gemcabene over intensive
standard of care as well as further explore the mechanism
of effect.
Gemcabene and a series of other carboxyalkylethers
were patented in 1995.24 The first preclinical data on gem-
cabene (PD72953) and select compounds of the series were
reported in 1998.26 Gemcabene was selected for further
development as a clinical candidate in 1998. The current
phase 2 study (NCT02571257) was conducted between
August 10, 2000 and April 15, 2002. The Investigational
New Drug (IND) application for the program was with-
drawn without prejudice in 2005. The gemcabene program
was licensed from Pfizer Inc. by Michigan Life Therapeu-
tics, LLC (currently Gemphire Therapeutics Inc.) in 2011,
and a new IND application for gemcabene was filed in 2015.
To date, gemcabene has been administered for up to
12 weeks to 895 healthy subjects and patients and has
been observed to be generally well tolerated to 900-mg
QD.27,28 The present study confirmed that treatment with
gemcabene in patients on stable statin therapy was well-
tolerated with a safety profile similar to statin therapy
alone. The results from this study support the continued
development of gemcabene as an adjunctive therapy to
lower LDL-C in patients with CVD unable to reach
goal with existing statin therapy and in patients without
CVD but severe hypercholesterolemia including HoFH
or heterozygous FH.
Stein et al Gemcabene in patients on stable statin therapy 1221Conclusions
In this phase 2 study, gemcabene 300 mg and 900 mg
showed placebo-corrected significant lowering of LDL-C
(17 and 22%) and CRP (15 and 43%) in hypercholester-
olemic patients on stable statin therapy. Importantly,
gemcabene (up to 900 mg for 8 weeks) was well-
tolerated with a safety profile similar to statin therapy
alone and supports the further development of gemcabene
as an adjunctive therapy to reduce LDL-C in patients
unable to reach goal with existing statin therapy.Acknowledgments
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